Czechia SUKL · July 27, 2026

First oral treatment for plaque psoriasis based on interleukin-23 receptor antagonist

Original title: První perorální léčba ložiskové psoriázy založená na bázi antagonisty receptoru pro interleukin-23

EMA recommended granting marketing authorisation for Icotyde (icotrokinra) in the European Union.

Low obligation Product class Pharmaceuticals Czech Republic Pharmaceuticals

Agentura EMA doporučila udělit registraci přípravku Icotyde (ikotrokinra) v Evropské unii.

Read the official source ↗

Published by Czechia SUKL. HealthSignal links to the original document; the summary above is extracted from the source text.